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Introduction: Adequate tumor acquisition is essential to iden-
tify somatic molecular alterations in non–small-cell lung cancer 
(NSCLC), such as epidermal growth factor receptor (EGFR) muta-
tions and anaplastic lymphoma kinase (ALK) translocations. The 
success and failure rates for tumor genotyping of tissue obtained 
from fine-needle aspirates of nodal tissue using a convex probe endo-
bronchial ultrasound (CP-EBUS) and other diagnostic modalities in 
 routine NSCLC care have not been described.
Methods: Clinicopathologic data, tumor genotype success and failure 
rates were retrospectively compiled and analyzed from 207 patient-
tumor samples sent for routine tumor genotype in clinical practice, 
including 42 patient-tumor samples obtained from hilar or mediasti-
nal lymph nodes using CP-EBUS.
Results: The median age of the patients was 65 years, 62.3% were 
women, 77.8% were white, 26.6% were never smokers, 73.9% had 
advanced NSCLC, and 84.1% had adenocarcinoma histology. Tumor 
tissue was obtained from CP-EBUS–derived hilar or mediastinal 
nodes in 42 cases (20.2% of total). In this latter cohort, the over-
all success rate for EGFR mutation analysis was 95.2%, for Kirsten 
rat sarcoma viral oncogene homolog (KRAS) mutation 90.5%, and 
for ALK fluorescence in situ hybridization 90.5%. In the complete 
207 tumors, the success rate for EGFR was 92.3%, for KRAS 91.8%, 
and for ALK 89.9%. The failure rates were not significantly differ-
ent when comparing CP-EBUS–derived nodal tissue versus all other 
samples or versus surgical biopsies of mediastinal nodes, but were 
significantly lower than image-guided percutaneous transthoracic 
core-needle biopsies.
Conclusions: The success rate of multiple tumor genomic analyses 
techniques for EGFR, KRAS, and ALK gene abnormalities using rou-
tine lung cancer tissue samples obtained from hilar or mediastinal 
lymph nodes by means of CP-EBUS exceeds 90%, and this method 
of tissue acquisition is not inferior to other specimen types. Tumor 
genotype techniques are feasible in most CP-EBUS–derived samples 
and therefore further expansion of routine tumor genotype for the 
care of patients with NSCLC may be possible using targeted sample 
acquisition through CP-EBUS.
Key Words: Lung cancer, Non–small-cell lung cancer, Endobronchial 
ultrasound, Mediastinoscopy, Never smokers, Epidermal growth fac-
tor receptor, Anaplastic lymphoma kinase, Kirsten rat sarcoma viral 
oncogene homolog, Tumor genotype, Failure, Bone specimen, Core 
biopsy, Transbronchial needle aspiration, Computed tomography, 
Molecular testing.
(J Thorac Oncol. 2013;8: 1438–1444)
Non–small-cell lung cancers (NSCLCs) comprise a het-erogeneous group of cancers characterized by different 
genomic abnormalities.1 In some NSCLCs, driver oncogenes 
have been identified, with the best studied including v-ki-ras2 
Kirsten rat sarcoma viral oncogene homolog (KRAS), epider-
mal growth factor receptor (EGFR), and anaplastic lymphoma 
kinase (ALK). Specifically, mutations in EGFR and rearrange-
ments involving ALK are part of the pathogenesis of NSCLCs 
(predominantly in never and/or light smokers) and predict 
improved outcomes with therapy based on tyrosine kinase 
inhibitors. Evidence-based practice guidelines now mandate 
adequate tissue acquisition for molecular studies aimed at 
identifying the aforementioned aberrations.2
Over the last decade, the development of convex 
probe endobronchial ultrasound (CP-EBUS) with capabil-
ity to obtain real-time visualization of mediastinal and hilar 
lymph nodes as well as guide transbronchial needle aspiration 
(TBNA) has revolutionized the diagnosis and staging of lung 
cancer. CP-EBUS offers a less invasive alternative for histo-
logic sampling of these nodal stations when compared with 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0811-1438
Adequacy of Lymph Node Transbronchial Needle Aspirates 
Using Convex Probe Endobronchial Ultrasound for 
Multiple Tumor Genotyping Techniques in Non–Small-Cell 
Lung Cancer
Erik Folch, MD, MSc,*† Norihiro Yamaguchi, MD, MPH,† Paul A. VanderLaan, MD, PhD,‡  
Olivier N. Kocher, MD, PhD,‡ David H. Boucher, BS,† Michael A. Goldstein, MD,†  
Mark S. Huberman, MD,† Michael S. Kent, MD,* Sidharta P. Gangadharan, MD,*  
Daniel B. Costa, MD, PhD,† and Adnan Majid, MD*†
Departments of *Surgery, †Medicine, ‡Pathology, Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, Massachusetts.
The first three authors contributed equally to this work.Disclosure: Dr. Daniel 
B. Costa has received consulting fees from Pfizer, Roche, and AstraZeneca. 
The other authors declare no conflict of interest.
Address for correspondence: Daniel B. Costa, MD, PhD, Division of 
Hematology/Oncology, Beth Israel Deaconess Medical Center, 
330 Brookline Avenue, Boston, MA 02215. E-mail: dbcosta@bidmc. 
harvard.edu
BRIEF REPORT
1439Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 11, November 2013 EBUS for Tumor Genotype
mediastinoscopy, and evidence-based guidelines of diagnosis 
and staging of lung cancer now suggest the use of CP-EBUS-
TBNA for the confirmation of suspected N2 and N3 disease. 
Several large prospective studies have demonstrated the 
sensitivity of CP-EBUS-TBNA to be equivalent to medias-
tinoscopy,3 the current standard procedure, in indicating the 
true pathologic N stage. However, in the case of restaging, 
CP-EBUS-TBNA allows for multiple, repeat biopsy events in 
a minimally invasive way, and thus confers an advantage over 
mediastinoscopy.4 When compared with other clinical staging 
strategies, CP-EBUS has diagnostic accuracy of 98% versus 
72.5% for positron emission tomography and 60.8% for com-
puted tomography.5 CP-EBUS-TBNA is an emerging method 
of tissue acquisition in NSCLC.
In the face of these two groundbreaking scientific 
advances—the characterization of the predictive value of 
driver oncogenes and the development of CP-EBUS as a 
method of tissue acquisition—it is evident that the combined 
use of CP-EBUS-TBNA and genotyping will likely impact the 
diagnosis, staging, and treatment of NSCLC. In this study, we 
aim to describe our experience in 207 patients with NSCLC 
who underwent diverse diagnostic procedures for genotypic 
analyses, with a focus on the group that had tumor acquisition 
through CP-EBUS-TBNA.
PATIENTS AND METHODS
Patient Selection
Patients with a diagnosis of lung cancer, who were seen 
by our providers and whose tumors were genotyped for at least 
EGFR mutations were retrospectively identified through an 
ongoing Institutional Review Board–approved protocol at Beth 
Israel Deaconess Medical Center (BIDMC2009-P-000182). 
Patients and tumor pairs were excluded if genotyping of at 
least EGFR mutation, KRAS mutation, and ALK translocations 
were not performed. There were 207 patient-tumor specimens 
that were submitted for these multiple tumor genotype tech-
niques between 2007 and 2012. The data cutoff for analyses 
was December 19, 2012. Study data were collected and man-
aged using REDCap electronic data capture tools hosted at 
Beth Israel Deaconess Medical Center.
Tumor Processing and Genotype
Surgical (i.e., either incisional or excisional biopsies that 
required a surgical procedure) and core-needle biopsies were 
processed using standard histopathologic techniques: 10% 
neutral buffered formalin fixation and paraffin embedding. 
Cell aspirates or cell concentrates from fluid samples were 
collected into a methanol–water fixative (CytoLyt; Hologic 
Corp., Marlborough, MA), with residual material used to cre-
ate a cell block using a plasma-thrombin method before for-
malin-fixation and paraffin embedding. Once a diagnosis was 
established on histologic and/or immunohistiologic slides, 
the residual material in the formalin-fixed paraffin-embedded 
tissue blocks were submitted for molecular analysis. When 
multiple tissue blocks were available, the one with the high-
est tumor cellularity was chosen, without additional tumor 
microdissection or enrichment. Molecular analysis of tumor 
specimens was performed by a commercial vendor, Integrated 
Oncology (LabCorp; Esoterix Genetic Laboratories, LLC). 
DNA was isolated and EGFR exons 18 to 21 were sequenced. 
For KRAS mutation analysis, exon 2 was amplified and sub-
jected to single nucleotide primer extension to detect muta-
tions at codons 12 and 13. ALK translocation status was 
analyzed using the Vysis ALK Break-Apart fluorescence in 
situ hybridization (FISH) probe (Abbott Molecular, Inc., Des 
Plaines, IL). Failure of the assays was defined as insufficient 
material to isolate DNA or inability to complete sequencing 
for EGFR and KRAS mutations, and lack of hybridization sig-
nals after two attempts for ALK FISH.
Data Collection
Data regarding the site of biopsy (lung, lymph node, 
pleura, bone, brain, liver, pericardium, or adrenal) and the 
type of biopsy (surgical specimen [both excisional or inci-
sional], core-needle biopsy or cell block from aspirate/fluid) 
were extracted from the medical record. Slides from all speci-
mens that failed molecular testing, as well as a subset of the 
successfully genotyped cases were rereviewed by a patholo-
gist (PAV), with data compiled on tissue preparation, tumor 
content, and other histological features annotated.
EBUS Technique and Tumor 
Collection with TBNA
The CP-EBUS bronchoscope used for tissue acquisi-
tion was a 7.5 MHz Olympus (BF-UC160F-OL8; Olympus 
America Inc., Center Valley, PA), fitted with color Doppler 
ultrasound capability. A 21-gauge needle was used to obtain 
TBNA samples. Two to eight passes (usually 3 passes) per 
lymph node were obtained. Lymph node stations reachable 
by CP-EBUS included paratracheal lymph nodes (2R, 2L, 4L, 
4R), subcarinal,6 and the hilar, interlobar, and lobar lymph 
nodes (10R, 10L, 11R, 11L, 12R, 12L). The lymph node aspi-
rates were placed in methanol–water fixative and prepared as 
described above. At our institution all CP-EBUS-TBNA cases 
were done by experienced interventional pulmonologists. As 
previously described, the learning curve on CP-EBUS-TBNA 
is likely to require 50 or more supervised cases to accomplish 
a systematic mediastinal staging.7
Statistical Methods
Fisher’s exact test was performed to compare categori-
cal variables. A p value less than 0.05 was considered statis-
tically significant. All p values reported were two-sided. We 
performed our statistical analyses with STATA version 12 
(StataCorp, College Station, TX).
RESULTS
Patient and Tumor Characteristics
Table 1 summarizes the clinical and pathological char-
acteristics of the 207 patient-tumor pairs that were included in 
our cohort and highlights the characteristics of the 42 samples 
(42 of 207; 20.2%) that were obtained from EBUS-derived 
mediastinal or hilar nodes (Table 1).
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TABLE 1.  Baseline Patient and Tumor Characteristics of the Overall Cohort and of the CP-EBUS-TBNA Cohort
All Patients (N = 207) CP-EBUS-TBNA Lymph Node Cohort (n = 42)
Age in years at the time of biopsy, median (range) 65 (29–89) 61.5 (39–84)
Women, n (%) 129 (62.3) 28 (66.7)
Race, n (%)
 White 161 (77.8) 34 (81.0)
 Asian 19 (9.18) 2 (4.76)
 Black 17 (8.21) 2 (4.76)
 Others 10 (4.83) 4 (9.52)
Smoking status, n (%)
 Current smoker 42 (20.3) 10 (23.8)
 Former smoker 110 (53.1) 23 (54.8)
 Never smoker 55 (26.6) 9 (21.4)
Stage, n (%)
 I 14 (6.76) 0 (0)
 II 13 (6.28) 1 (2.38)
 III 27 (13.0) 7 (16.7)
 IV 153 (73.9) 34 (81.0)
Histology, n (%)
 Adenocarcinoma 174 (84.1) 36 (85.7)
 Squamous cell carcinoma 9 (4.35) 0 (0)
 NSCLC (NOS) 22 (10.6) 6 (14.3)
 Others 2 (0.97) 0 (0)
Anatomic site of biopsy, n (%)
 Bone 13 (6.28) 0 (0)
 Brain 17 (8.21) 0 (0)
 Liver 3 (1.45) 0 (0)
 Lung 98 (47.3) 0 (0)
 Lymph node 51 (24.6) 42 (100)
 Pleura 23 (11.1) 0 (0)
 Others 2 (0.97) 0 (0)
Type of biopsy, n (%)
 Core-needle biopsy 39 (18.8) 0 (0)
 Surgical biopsy 95 (45.9) 0 (0)
 Cell block from FNA 61 (29.5) 42 (100)
 Cell block from fluid 12 (5.80) 0 (0)
EGFR mutation analysis
 Success, n (%, [95% CI]) 191 (92.3 [87.5–95.4]) 40 (95.2 [82.6–99.2])
  Positive/mutated 32 (15.5) 5 (11.9)
  Negative/wild-type 159 (76.8) 35 (83.3)
 Failure 16 (7.73) 2 (4.8)
KRAS mutation analysis
 Success, n (%, [95% CI]) 190 (91.8 [87.0–95.0]) 38 (90.5 [76.5–96.9])
  Positive/mutated 65 (31.4) 18 (42.9)
  Negative/wild-type 125 (60.4) 20 (47.6)
 Failure 17 (8.21) 4 (9.5)
ALK FISH analysis
 Success, n (%, [95% CI]) 186 (89.9 [84.7–93.5]) 38 (90.5 [76.5–96.9])
  Positive 11 (5.31) 1 (2.4)
  Negative 175 (84.5) 37 (88.1)
 Failure 21 (10.1) 4 (9.5)
CI, confidence interval; CP-EBUS-TBNA, convex probe endobronchial ultrasound transbronchial needle aspiration; NSCLC, non–small-cell lung cancer; FNA, fine-needle 
aspiration; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; 
NOS, not otherwise specified.
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Success and Failure Rates of Tumor 
Genotype Techniques
In these 207 tumors, all three tests were ordered 
simultaneously. The success rate for EGFR mutation anal-
ysis was 92.3%, for KRAS mutation 91.8%, and for ALK 
FISH 89.9%.
In the 42 lymph node metastases obtained through 
EBUS-TBNA, the success rate for EGFR mutation analysis 
was 95.2%, for KRAS mutation 90.5%, and for ALK FISH 
90.5% (Table 1).
CP-EBUS–Derived Nodal Tissue Compared 
with Other Tissue-Acquisition Techniques
To determine whether CP-EBUS–derived nodal tis-
sue had similar or different success rates when compared 
with other possible methods of tumor acquisition, we first 
compared CP-EBUS–derived nodal tissue with all remain-
ing samples. Typical histologic examples of image-guided 
percutaneous transthoracic core-needle biopsies, broncho-
scopic-guided lung biopsies, and cell blocks prepared from 
CP-EBUS-TBNAs of mediastinal lymph nodes are compared 
in Figure 1.
CP-EBUS–derived nodal tissues were obtained from N1, 
N2, and/or N3 nodes, the median number of fine-needle aspira-
tion passes per node was 3.28 (range, 2–8), and there were no 
reported complications. As indicated in Table 2, the failure rates 
were not significantly different between CP-EBUS–derived 
nodal tissue versus all other samples for EGFR mutation, for 
KRAS mutation, and for ALK FISH (Table 2).
To better match the tissue of origin (thoracic lymph 
nodes), we compared the success and failure rates of 
CP-EBUS-TBNA with those of mediastinal or hilar nodes 
acquired through surgical biopsies (either through medias-
tinoscopy or thoracic resections). There were no failures in 
the eight nodal tissues acquired through surgical technique. 
However, the success rates were not significantly different 
between CP-EBUS–derived nodal tissue versus these eight 
surgical nodal specimens for EGFR mutation; for KRAS muta-
tion and for ALK FISH (Table 2).
We then compared CP-EBUS–derived nodal tissue 
with lung biopsies, either using image-guided percutaneous 
transthoracic core-needle biopsies or lung biopsies obtained 
through bronchoscopy (Table 2). The success rates were 
higher when CP-EBUS–derived nodal tissue was compared 
with image-guided percutaneous transthoracic core-needle 
biopsies for EGFR mutation, for KRAS mutation, and for 
ALK FISH (Table 2). The success rates for CP-EBUS–derived 
nodal tissue were similar to those of bronchoscopy-guided 
lung biopsies (Table 2).
We compared image-guided percutaneous transthoracic 
core-needle and bronchoscopy-guided lung biopsies in rela-
tion to estimated tumor cellularity, tumor area, use of touch 
preparation for rapid on-site evaluation, presence of extensive 
desmoplastic stromal response, number of slides cut from the 
paraffin block used for immunohistochemical/ancillary stud-
ies, number of biopsy passes, location site within the lung, and 
mass size. The only two major differences were in the use of 
a touch preparation (image-guided percutaneous transthoracic 
core-needle biopsies 8 of 8 cases versus 0 of 13 cases for 
bronchoscopy-guided lung biopsies; p < 0.0001) and the num-
ber of passes of needle for tissue acquisition (image-guided 
percutaneous transthoracic core-needle biopsies 8 of 11 cases 
with ≤2 passes versus 0 of 14 cases for bronchoscopy-guided 
lung transbronchial biopsies; p = 0.072). Complications, 
including pneumothorax, were also more common in image-
guided percutaneous transthoracic core-needle biopsies (6 of 
11 cases) when compared with bronchoscopy-guided lung 
biopsies (0 of 14 cases; p = 0.009).
Failed Specimens Using CP-EBUS–Derived  
Nodal Tissue
We attempted to determine factors specifically associ-
ated with molecular testing failure in specimens originating 
from CP-EBUS. In most of the samples that failed at least one 
of the tumor genotyping techniques used, we observed that 
there were insufficient tumor cells in the cell block specimen 
(<100 tumor cells per slide and inferior dimension of tumor 
specimen). In CP-EBUS–derived nodal tissues that were suc-
cessful 17 of 19 (89.4%) had 100 cells or more whereas in 
failure cases only two of five (40%) had 100 cells or more (p 
= 0.042). We also evaluated as other possible characteristics 
the size of the nodal tissue biopsied, the location of the node, 
the number of passes per lymph node, use of touch prepara-
tion for rapid on-site evaluation, presence of extensive des-
moplastic stromal response, and number of slides cut from 
the paraffin block used for immunohistochemical and ancil-
lary studies. None of these characteristics were significantly 
different between success and failure in CP-EBUS–derived 
nodal samples.
DISCUSSION
In this study, we provide evidence that CP-EBUS-
TBNA is able to procure adequate lymph node tissue to carry 
out genetic analyses of EGFR, KRAS, and ALK using com-
mercially available techniques that are used for everyday 
patient care. More than 20% of tumor samples submitted for 
tumor genotype at our academic medical center originated 
from CP-EBUS-TBNA of hilar or mediastinal nodes. In these 
metastases, the success rate for EGFR mutation analysis was 
95.2%, for KRAS mutation 90.5%, and for ALK FISH 90.5%. 
More importantly, these CP-EBUS-TBNA samples were not 
inferior to surgical thoracic nodal samples and/or to image-
guided percutaneous transthoracic core-needle biopsies in our 
single-institution series; results that may not reflect practice 
patterns at other centers.
The clinician (a medical oncologist, thoracic surgeon, or 
pulmonologist) is frequently faced with the choice of diagnos-
tic sampling technique. Traditionally, image-guided percutane-
ous transthoracic core-needle biopsies have been used by most 
practices to obtain tissue from peripheral lung tumors even 
in the presence of hilar and/or mediastinal thoracic lymph-
adenopathy. However, our study shows that when compared 
with CP-EBUS–guided biopsies, image-guided percutaneous 
transthoracic core-needle biopsies of the lung had a signifi-
cantly higher failure rate of tumor genotype techniques. The 
high failure rate of image-guided percutaneous transthoracic 
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core-needle biopsies to yield adequate material for molecu-
lar studies has been reported by other academic medical cen-
ters.8 It is possible to speculate that tumor tissue loss during 
the aforementioned procedure and subsequent preparation 
explains these results. Indeed, in our series, image-guided per-
cutaneous transthoracic core-needle biopsies more frequently 
had tissue loss (in the form of cytological adequacy evalua-
tion of core biopsy touch-preparation slides at time of biopsy) 
than bronchoscopic-derived lung biopsies. Interestingly, the 
absence of rapid on-site evaluation for CP-EBUS procedures 
did not seem to affect the success rate in our series and may 
have indeed led to a more thorough evaluation and repeated 
sampling of the lymph nodes. Also of note, in traditional 
image-guided percutaneous transthoracic core-needle biopsies 
of the lung there is an increased risk of complications (includ-
ing pneumothorax) when doing multiple needle passes; a con-
cern that is not significant with CP-EBUS-TBNA.6 However, 
the importance of extensive training in CP-EBUS-TBNA, 
FIGURE 1.  Histopathology of different minimally invasive methods for thoracic tissue sampling. A and B, Image-guided percu-
taneous transthoracic core-needle biopsies from a left upper lobe lung mass. The low-power field highlights one of two needle 
core biopsies obtained, both demonstrating significant fibrosis with intervening areas of invasive adenocarcinoma. On higher 
power, the tumor cells demonstrate a glandular structure, with associated chronic inflammation. Cytologic rapid on-site evalu-
ation of touch prep slides from the core biopsies confirmed adenocarcinoma, and subsequent tumor genotyping successfully 
identified a deletion mutation in exon 19 of the EGFR gene. C and D, Bronchoscopy-guided lung biopsies of a right middle lobe 
lung mass. The low-power field in (C) shows two of the six airway tissue biopsies obtained. The higher-power view demonstrates 
a poorly differentiated adenocarcinoma with cytoplasmic mucin vacuoles infiltrating submucosal lymphatic spaces, with sur-
rounding bronchial associated lymphoid tissue and overlying respiratory epithelium. Tumor genotyping successfully identified 
a mutation in exon 20 of the EGFR gene. E and F, Cell block preparation from a convex probe endobronchial ultrasound trans-
bronchial needle aspiration of mediastinal lymph nodes. The low-power field view in (E), covering approximately 25% of the cell 
block area, highlights the cellular specimen with numerous clusters of tumor cells in a background of eosinophilic fibrin clot. On 
higher power the background lymphocytes confirm lymph node sampling, and the tumor structure is that of a moderately dif-
ferentiated adenocarcinoma. Tumor genotyping was successful. A, C, and E, ×40 original magnification; B, D, and F, ×200 original 
 magnification representing boxed area in prior panel; hematoxylin and eosin stains. EGFR, epidermal growth factor receptor.
1443Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 11, November 2013 EBUS for Tumor Genotype
particularly in complete and systematic staging for lung can-
cer, cannot be overemphasized.7
The use of CP-EBUS-TBNA for tumor genotype in 
NSCLC has been reported by a few other groups, with success-
ful analysis of at least one genotype (such as EGFR or KRAS 
mutations) in 72.2% to 98.4% of samples obtained.9–14 One of 
the largest published series described a cohort of 774 patients 
in five centers of the United Kingdom with known or suspected 
lung cancer on whom CP-EBUS-TBNA was done to determine 
whether these samples were suitable for NSCLC subclassifica-
tion and genotyping. The available tissue allowed subclassifi-
cation of 77% of samples and genotyping for EGFR mutation 
in 90% of the cases.15 In our study, all samples were obtained 
using routine day-to-day procedures, underwent routine patho-
logical subtyping with immunohistochemical markers, and then 
were subsequently sent for multiple tumor genotype analyses 
with a success rate that exceeded 90%. The aforementioned 
studies confirm that CP-EBUS-TBNA samples are adequate as 
a starting material for routine tumor genotype studies.
In summary, commercially available tumor genotype 
techniques for EGFR mutation analysis, KRAS mutation 
analysis, and ALK FISH are feasible in most EBUS-TBNA 
NSCLC samples. These encouraging findings may indicate 
that further expansion of routine tumor genotype into the care 
of patients with NSCLC may be possible using targeted sam-
ple acquisition through EBUS.
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